GOTHENBURG, SE / ACCESSWIRE / November 28, 2022 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) XVIVO continues to grow and strengthen the business. XVIVO has a firm strategic plan for the next five years and Lena Hagman has been appointed COO as part of securing the company’s global market leadership position.

Lena Hagman has extensive global operational experience in the medtech industry, having held various management positions within the Getinge Group – a Swedish global medtech company – over the past 12 years. Most recently, she was Executive Vice President for Quality Compliance, Regulatory and Medical Affairs for seven years.

She has been involved in the medical device industry throughout her career, with more than 20 years in senior positions with global responsibilities in research and development, supply chain and quality/regulatory/medical affairs. Over the years, Lena has led many strategy and efficiency programs and corporate integrations. With her in-depth knowledge and experience of various global quality regulations for medical devices and with a high focus on customer and patient centricity, she will make a great contribution to the XVIVO leadership team.

She has a B.Sc. in Chemistry and Textile Engineering from Chalmers University of Technology, Sweden. Lena will be based at the Gothenburg headquarters and will start on December 1st, 2022.

“I am delighted that we have recruited a highly qualified COO to lead the development of the Operations function. Having Lena on board with her extensive experience from various leadership positions will not only strengthen the management team but also stabilize XVIVO’s continued growth trajectory,” says Christoffer Rosenblad, Acting CEO of XVIVO.

November 28, 2022
Gothenburg
Christopher Rosenblad, Acting CEO
XVIVO Perfusion AB (ed.)

For more information please contact:

Christoffer Rosenblad, acting CEO, +46 73 519 21 59, email: